Bank of New York Mellon Corp Buys 3,815 Shares of AngioDynamics, Inc. (NASDAQ:ANGO)

Bank of New York Mellon Corp increased its stake in shares of AngioDynamics, Inc. (NASDAQ:ANGO) by 3.2% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,676 shares of the medical instruments supplier’s stock after purchasing an additional 3,815 shares during the quarter. Bank of New York Mellon Corp’s holdings in AngioDynamics were worth $1,124,000 as of its most recent SEC filing.

Other institutional investors also recently added to or reduced their stakes in the company. Rhumbline Advisers lifted its position in shares of AngioDynamics by 1.7% during the fourth quarter. Rhumbline Advisers now owns 60,479 shares of the medical instruments supplier’s stock valued at $554,000 after buying an additional 1,021 shares during the last quarter. Quarry LP lifted its position in AngioDynamics by 40.9% during the third quarter. Quarry LP now owns 8,518 shares of the medical instruments supplier’s stock valued at $66,000 after acquiring an additional 2,471 shares during the last quarter. SG Americas Securities LLC boosted its stake in AngioDynamics by 21.3% in the fourth quarter. SG Americas Securities LLC now owns 16,102 shares of the medical instruments supplier’s stock valued at $147,000 after acquiring an additional 2,832 shares in the last quarter. R Squared Ltd purchased a new position in AngioDynamics in the fourth quarter worth $49,000. Finally, Charles Schwab Investment Management Inc. increased its position in shares of AngioDynamics by 3.7% during the third quarter. Charles Schwab Investment Management Inc. now owns 326,820 shares of the medical instruments supplier’s stock worth $2,543,000 after purchasing an additional 11,599 shares in the last quarter. Institutional investors own 89.43% of the company’s stock.

AngioDynamics Stock Up 1.6 %

Shares of AngioDynamics stock opened at $10.08 on Tuesday. The company has a 50 day moving average price of $10.60 and a 200 day moving average price of $8.74. The firm has a market capitalization of $407.90 million, a P/E ratio of -1.79 and a beta of 0.56. AngioDynamics, Inc. has a 52 week low of $5.26 and a 52 week high of $13.50.

AngioDynamics (NASDAQ:ANGO) last posted its quarterly earnings results on Wednesday, January 8th. The medical instruments supplier reported ($0.04) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.07. The business had revenue of $72.90 million during the quarter, compared to analysts’ expectations of $70.93 million. AngioDynamics had a negative net margin of 79.38% and a negative return on equity of 7.26%. The business’s quarterly revenue was down .1% on a year-over-year basis. During the same quarter last year, the company posted ($0.05) earnings per share. As a group, research analysts anticipate that AngioDynamics, Inc. will post -0.37 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, SVP Warren Nighan, Jr. sold 4,060 shares of the company’s stock in a transaction that occurred on Thursday, January 16th. The stock was sold at an average price of $12.31, for a total value of $49,978.60. Following the sale, the senior vice president now owns 41,817 shares in the company, valued at $514,767.27. This represents a 8.85 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 5.40% of the stock is currently owned by insiders.

Analyst Ratings Changes

Separately, HC Wainwright raised their price objective on AngioDynamics from $14.00 to $15.00 and gave the stock a “buy” rating in a research report on Friday, January 10th.

About AngioDynamics

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.